Targeting Mutant KRAS for Immunogenic Cell Death Induction

Lorenzo Galluzzi

doi:10.1016/j.tips.2019.11.004

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Lorenzo Galluzzi

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRAS^G12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.

Original language	English
Pages (from-to)	1-3
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	41
Issue number	1
DOIs	https://doi.org/10.1016/j.tips.2019.11.004
State	Published - Jan 2020
Externally published	Yes

Keywords

colorectal cancer
lung adenocarcinoma
nivolumab
oxaliplatin
pembrolizumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tips.2019.11.004

Cite this

@article{4bb2b93436b24d82bf3bba85cd00a792,

title = "Targeting Mutant KRAS for Immunogenic Cell Death Induction",

abstract = "Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.",

keywords = "colorectal cancer, lung adenocarcinoma, nivolumab, oxaliplatin, pembrolizumab",

author = "Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2020",

month = jan,

doi = "10.1016/j.tips.2019.11.004",

language = "English",

volume = "41",

pages = "1--3",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Targeting Mutant KRAS for Immunogenic Cell Death Induction

AU - Galluzzi, Lorenzo

PY - 2020/1

Y1 - 2020/1

N2 - Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.

AB - Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.

KW - colorectal cancer

KW - lung adenocarcinoma

KW - nivolumab

KW - oxaliplatin

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85076245723&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2019.11.004

DO - 10.1016/j.tips.2019.11.004

M3 - Short survey

C2 - 31818506

AN - SCOPUS:85076245723

SN - 0165-6147

VL - 41

SP - 1

EP - 3

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 1

ER -

Targeting Mutant KRAS for Immunogenic Cell Death Induction

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this